President, Head of Research & Development and Chief Medical Officer, Senti Biosciences
Search every verified Kanya Rajangam interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Kanya Rajangam, President, Head of Research and Development, and Chief Medical Officer at Senti Biosciences, has discussed the company's progress with its lead candidate SENTI-202, a logic-gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy for relapsed/refractory acute myeloid leukemia (AML). In 2025 appearances, she described the selection and confirmation of a recommended Phase 2 dose (RP2D) using a 3+3 trial design, the opening of an expansion cohort, and a goal of enrolling approximately 20 patients by year-end. She also reported data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, including deep responses with MRD-negative complete remissions in four of seven patients, and stated that correlative and preclinical data supported the function of the therapy's logic gate in targeting leukemia cells while preserving healthy cells. Rajangam has also discussed the broader context of the SENTI-202 program, noting that determining the RP2D is a key milestone in Phase 1 trials and that the company is focused on AML for the current year while exploring applications of its gene circuit approach to other cancers, including solid tumors. In earlier remarks from 2022, she described the path to investigational new drug (IND) filings for SENTI-202 and another program, SENTI-301, emphasizing the company's work on gene circuits in allogeneic cell therapy and the potential advantages of natural killer cells in this setting.
Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company’s recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy, SENTI-202, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio.
Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Tim Lu - Co-Founder & Chief Executive Officer Tim Lu has served as CEO since he co-founded Senti Bio in 2016. Lu joined the MIT faculty in 2010 in the departments of Biological Engineering and Electrical Engineering and Computer Science. In addition, Lu has been a co-founder and a Scientific Advisory Board member to a number of biotechnology and biopharmaceutical companies, including Tango Therapeutics, Synlogic, Engine Biosciences, BiomX, Corvium, and Eligo Bioscience. Lu earned his M.D. from Harvard Medical School and his Ph.D. in Electrical and Biomedical Engineering from Massachusetts In…
Sign in to search the full transcript archive, filter by topic, and access every quote from Kanya Rajangam.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans